YU13701A - GnRH SREDSTVA KOJA NISU PEPTIDI, POSTUPCI I INTERMEDIJERI ZA NJIHOVO DOBIJANJE - Google Patents
GnRH SREDSTVA KOJA NISU PEPTIDI, POSTUPCI I INTERMEDIJERI ZA NJIHOVO DOBIJANJEInfo
- Publication number
- YU13701A YU13701A YU13701A YU13701A YU13701A YU 13701 A YU13701 A YU 13701A YU 13701 A YU13701 A YU 13701A YU 13701 A YU13701 A YU 13701A YU 13701 A YU13701 A YU 13701A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- preparation
- methods
- intermediates
- peptide gnrh
- gnrh agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Opisani su nepeptidni GnRH agensi sposobni za inhibiranje efekta hormona koji oslobadja gonadotropin. Takva jedinjenja i njihove farmaceutski prihvatljive soli, multimeri, ciljni lekovi, i aktivni metaboliti pogodni su za lečenje reproduktivnih poremećaja kod sisara i tumora koji su zavisni od steroidnih hormona kao i za regulisanje plodnosti, kada se pokazuje suzbijanje oslobadjanja gonadotropina. Postupci za sintetizovanje jedinjenja i intermedijera korisnih za njihovo dobijanje takodje su opisani.[Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9752098P | 1998-08-20 | 1998-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU13701A true YU13701A (sh) | 2005-06-10 |
Family
ID=22263796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU13701A YU13701A (sh) | 1998-08-20 | 1999-08-20 | GnRH SREDSTVA KOJA NISU PEPTIDI, POSTUPCI I INTERMEDIJERI ZA NJIHOVO DOBIJANJE |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1105120B1 (sh) |
JP (1) | JP2002535244A (sh) |
KR (1) | KR20010085402A (sh) |
CN (1) | CN1379666A (sh) |
AP (1) | AP2001002053A0 (sh) |
AT (1) | ATE291423T1 (sh) |
AU (1) | AU759310B2 (sh) |
BG (1) | BG105362A (sh) |
BR (1) | BR9913374A (sh) |
CA (1) | CA2341346A1 (sh) |
CZ (1) | CZ2001523A3 (sh) |
DE (1) | DE69924387D1 (sh) |
EA (1) | EA200100255A1 (sh) |
EE (1) | EE200100102A (sh) |
ES (1) | ES2237966T3 (sh) |
GE (1) | GEP20043315B (sh) |
HR (1) | HRP20010206A2 (sh) |
HU (1) | HUP0103622A3 (sh) |
ID (1) | ID29244A (sh) |
IL (1) | IL141396A0 (sh) |
IS (1) | IS5846A (sh) |
LT (1) | LT4904B (sh) |
LV (1) | LV12732B (sh) |
NO (1) | NO20010309L (sh) |
NZ (1) | NZ509252A (sh) |
OA (1) | OA11599A (sh) |
PL (1) | PL356984A1 (sh) |
SI (1) | SI20746A (sh) |
SK (1) | SK2262001A3 (sh) |
TR (1) | TR200100631T2 (sh) |
WO (1) | WO2000020358A2 (sh) |
YU (1) | YU13701A (sh) |
ZA (1) | ZA200100831B (sh) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE307795T1 (de) * | 1992-04-22 | 2005-11-15 | Ligand Pharm Inc | Verbindungen mit retinoid x rezeptorselektivität |
JP2003524620A (ja) * | 1999-03-24 | 2003-08-19 | アノーメッド インコーポレイティド | ケモカインレセプター結合複素環化合物 |
CO5370679A1 (es) * | 1999-06-01 | 2004-02-27 | Smithkline Beecham Corp | Inhibidores fab 1 |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
MXPA03011002A (es) * | 2001-06-06 | 2004-10-28 | Agouron Pharma | Agentes gnrh no peptidicos, composiciones farmaceuticas y procedimientos para su uso y procesos para prepararlos a ellos y a sus intermedios. |
SK288015B6 (sk) * | 2001-06-11 | 2012-11-05 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
WO2003030902A1 (en) | 2001-10-09 | 2003-04-17 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
GB0126292D0 (en) * | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
JP2005170790A (ja) * | 2002-01-09 | 2005-06-30 | Ajinomoto Co Inc | N−アルキルスルフォニル置換アミド誘導体 |
US6521395B1 (en) * | 2002-01-30 | 2003-02-18 | Eastman Kodak Company | Infrared couplers for incorporating and recovering metadata |
WO2003068769A1 (en) * | 2002-02-12 | 2003-08-21 | Pfizer Inc. | Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh) |
TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
CA2489252A1 (en) * | 2002-06-13 | 2003-12-24 | Pfizer Inc. | Non-peptide gnrh agents, pharmaceutical compositions and methods for their use |
DE60307313T2 (de) * | 2002-11-20 | 2006-12-14 | Paradigm Therapeutics Ltd. | Heterozyklische siliziumverbindungen und deren verwendung zur behandlung von krankheiten oder zuständen, die mit gnrh (gonadotropinfreisetzendem hormon) assoziiert sind |
CN101475528A (zh) * | 2003-03-31 | 2009-07-08 | 大正制药株式会社 | 新的喹啉、四氢喹唑啉和嘧啶衍生物以及与其应用有关的治疗方法 |
EP1464335A3 (en) * | 2003-03-31 | 2007-05-09 | Taisho Pharmaceutical Co. Ltd. | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist |
US7427683B2 (en) * | 2003-04-25 | 2008-09-23 | Ortho-Mcneil Pharmaceutical, Inc. | c-fms kinase inhibitors |
MXPA05011503A (es) * | 2003-04-25 | 2006-05-31 | Johnson & Johnson | Inhibidores de la c-fms cinasa. |
US20050004133A1 (en) * | 2003-06-05 | 2005-01-06 | Makings Lewis R. | Modulators of VR1 receptor |
US20070111967A1 (en) * | 2003-07-09 | 2007-05-17 | Miller David J | Organosilicon compounds and their use |
EP1644385B1 (en) * | 2003-07-10 | 2007-08-29 | Takeda Cambridge Limited | Silicon compounds and their use |
WO2005039564A1 (en) * | 2003-10-02 | 2005-05-06 | Vertex Pharmaceuticals Incorporated | Phthalimide compounds useful as protein kinase inhibitors |
US20090291915A1 (en) * | 2004-12-17 | 2009-11-26 | Graham Andrew Showell | Silicon Compounds and Their Use |
AP2007004245A0 (en) | 2005-05-13 | 2007-12-31 | Virochem Pharma Inc | Compounds and methods for the treatment or prevention of flavivirus infections |
JP5118029B2 (ja) | 2005-06-14 | 2013-01-16 | タイゲン バイオテクノロジー カンパニー,リミテッド | ピリミジン化合物 |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
CA2613162A1 (en) * | 2005-06-28 | 2007-01-04 | Takeda Cambridge Limited | Heterocyclic non-peptide gnrh antagonists |
AU2006278397B2 (en) * | 2005-08-04 | 2013-01-17 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
JP5255559B2 (ja) | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
WO2007131996A1 (en) * | 2006-05-12 | 2007-11-22 | Genmedica Therapeutics Sl | Meta-xylylenediamine vanadate salts |
TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
MX2010003866A (es) * | 2007-10-11 | 2010-06-01 | Vertex Pharma | Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. |
NZ585587A (en) | 2007-10-31 | 2012-04-27 | Res Found Itsuu Lab | Retinoid prodrug compound |
PT2268635E (pt) | 2008-04-21 | 2015-10-06 | Taigen Biotechnology Co Ltd | Compostos heterocíclicos |
UY31984A (es) * | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
WO2010056847A2 (en) | 2008-11-13 | 2010-05-20 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
EP2611784A4 (en) | 2010-08-05 | 2014-01-08 | Amgen Inc | BENZIMIDAZOLE AND AZABENEZIMIDAZOLE COMPOUNDS FOR INHIBITING THE ANAPLASTIC LYMPHOMINE KINASE |
CN102050823A (zh) * | 2010-10-27 | 2011-05-11 | 华东理工大学 | 新型光稳定剂-鸟嘌呤类似物的合成及表征 |
US9199918B2 (en) * | 2011-02-15 | 2015-12-01 | Georgetown University | Small molecule inhibitors of AGBL2 |
JP6254075B2 (ja) | 2011-05-16 | 2017-12-27 | バイオノミックス リミテッド | カリウムチャネル遮断剤としてのアミン誘導体 |
EP3037417B1 (en) | 2011-07-26 | 2019-05-22 | Sanofi | 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
US9586914B2 (en) | 2011-11-07 | 2017-03-07 | The University Of Queensland | Modulators of C3a receptors |
JP2016504270A (ja) * | 2012-10-17 | 2016-02-12 | ザ ユニバーシティ オブ ブリストル | 眼血管形成(ocularneovasculan)を治療するのに有用な化合物 |
GB201300304D0 (en) * | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
WO2017070235A1 (en) * | 2015-10-19 | 2017-04-27 | Attenua, Inc. | Antitussive compositions and methods |
CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
EP3935050A4 (en) | 2019-03-06 | 2023-01-04 | C4 Therapeutics, Inc. | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3499002A (en) * | 1968-06-20 | 1970-03-03 | Robins Co Inc A H | 1-carbamoyl-3-aroylpyrrolidines |
NL6913261A (sh) * | 1968-09-09 | 1970-03-11 | ||
US3932444A (en) * | 1972-04-28 | 1976-01-13 | E. I. Du Pont De Nemours & Co. | 4-Imidazolylsulfonylimidazoles |
US4013647A (en) * | 1976-03-23 | 1977-03-22 | American Home Products Corporation | Morpholine containing tetrazole-5-carboxamide derivatives |
GB1491776A (en) * | 1976-09-08 | 1977-11-16 | Pfizer Ltd | Thiadiazoles |
US4076718A (en) * | 1977-01-21 | 1978-02-28 | American Home Products Corporation | 2,6-Pyridinediyl-bis-tetrazol-5-carboxamides |
US5236928A (en) * | 1991-03-19 | 1993-08-17 | Merck & Co., Inc. | Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists |
EP0592512A1 (en) | 1991-07-01 | 1994-04-20 | University Technologies International Inc. (Uti) | NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS |
US5622976A (en) * | 1991-12-31 | 1997-04-22 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
EP0761654B1 (en) * | 1995-08-24 | 2003-06-18 | Basf Aktiengesellschaft | Isoxazole- and isothiazole-5-carboxamide derivatives, their preparation and their use as herbicides |
WO1997021707A1 (en) * | 1995-12-14 | 1997-06-19 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
JP2000511532A (ja) * | 1996-05-20 | 2000-09-05 | メルク エンド カンパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモンのアンタゴニスト |
US5878393A (en) * | 1996-09-09 | 1999-03-02 | Matsushita Electric Industrial Co., Ltd. | High quality concatenative reading system |
-
1999
- 1999-08-20 TR TR2001/00631T patent/TR200100631T2/xx unknown
- 1999-08-20 PL PL99356984A patent/PL356984A1/xx unknown
- 1999-08-20 IL IL14139699A patent/IL141396A0/xx unknown
- 1999-08-20 HU HU0103622A patent/HUP0103622A3/hu unknown
- 1999-08-20 SI SI9920076A patent/SI20746A/sl not_active IP Right Cessation
- 1999-08-20 EE EEP200100102A patent/EE200100102A/xx unknown
- 1999-08-20 AP APAP/P/2001/002053A patent/AP2001002053A0/en unknown
- 1999-08-20 EP EP99968010A patent/EP1105120B1/en not_active Expired - Lifetime
- 1999-08-20 GE GE4368A patent/GEP20043315B/en unknown
- 1999-08-20 KR KR1020017002021A patent/KR20010085402A/ko not_active Application Discontinuation
- 1999-08-20 BR BR9913374-1A patent/BR9913374A/pt not_active IP Right Cessation
- 1999-08-20 NZ NZ509252A patent/NZ509252A/en unknown
- 1999-08-20 OA OA1200100043A patent/OA11599A/en unknown
- 1999-08-20 EA EA200100255A patent/EA200100255A1/ru unknown
- 1999-08-20 DE DE69924387T patent/DE69924387D1/de not_active Expired - Fee Related
- 1999-08-20 ID IDW20010406A patent/ID29244A/id unknown
- 1999-08-20 CA CA002341346A patent/CA2341346A1/en not_active Abandoned
- 1999-08-20 JP JP2000574479A patent/JP2002535244A/ja active Pending
- 1999-08-20 YU YU13701A patent/YU13701A/sh unknown
- 1999-08-20 WO PCT/US1999/018790 patent/WO2000020358A2/en not_active Application Discontinuation
- 1999-08-20 ES ES99968010T patent/ES2237966T3/es not_active Expired - Lifetime
- 1999-08-20 CN CN99812285A patent/CN1379666A/zh active Pending
- 1999-08-20 AU AU24709/00A patent/AU759310B2/en not_active Ceased
- 1999-08-20 CZ CZ2001523A patent/CZ2001523A3/cs unknown
- 1999-08-20 AT AT99968010T patent/ATE291423T1/de not_active IP Right Cessation
- 1999-08-20 SK SK226-2001A patent/SK2262001A3/sk unknown
-
2001
- 2001-01-19 NO NO20010309A patent/NO20010309L/no not_active Application Discontinuation
- 2001-01-30 ZA ZA200100831A patent/ZA200100831B/en unknown
- 2001-02-16 IS IS5846A patent/IS5846A/is unknown
- 2001-03-16 LV LVP-01-45A patent/LV12732B/en unknown
- 2001-03-19 BG BG105362A patent/BG105362A/xx unknown
- 2001-03-19 LT LT2001024A patent/LT4904B/lt unknown
- 2001-03-20 HR HR20010206A patent/HRP20010206A2/hr not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU13701A (sh) | GnRH SREDSTVA KOJA NISU PEPTIDI, POSTUPCI I INTERMEDIJERI ZA NJIHOVO DOBIJANJE | |
LV12631A (en) | Non-peptide gnrh agents | |
MXPA03001320A (es) | Agentes no peptidicos de la gnrh, composiciones farmaceuticas y procedimientos para su uso. | |
IL124459A0 (en) | Antagonists of gonadotropin releasing hormone | |
MX9804850A (es) | Antagonistas de hormona liberadora de gonadotropina. | |
NZ325060A (en) | Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone | |
EP1862167A3 (en) | Methods and formulations for the treatment of female sexual dysfunction | |
ES2109995T3 (es) | Procedimiento y composiciones de contracepcion y de tratamiento de alteraciones ginecologicas benignas. | |
WO2002098363A3 (en) | NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM | |
PE55998A1 (es) | Derivados 19-nor-pregneno substituidos | |
MXPA02010066A (es) | Estratrienos sustituidos en 8beta-hidrocarbilo para uso como estrogenos selectivos. | |
GR3030164T3 (en) | Treatment of ovarian estrogen dependent conditions | |
DK279790A (da) | Aromatiske steroid-5-alfa-reduktaseinhibitorer | |
SG188700A1 (en) | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors | |
NO20005145D0 (no) | FremgangsmÕte for behandling av fertilitetsproblemer | |
Leihy et al. | Virilization of the urogenital sinus of the tammar wallaby is not unique to 5α-androstane-3α, 17β-diol | |
WO2003104253A3 (de) | 9-alpha-substituierte estratriene als selektiv wirksame estrogene | |
CA2406846A1 (en) | Pharmacotherapeutic process and composition for central nervous system disorders | |
MX9300677A (es) | Procedimiento mejorado para la preparacion de dienos esteroidales substituidos. | |
JPS5236654A (en) | Process for preparation of steroid derivatives |